Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2014

01-12-2014 | Research Article

The functional proteomics analysis of VEGF-treated human epithelial ovarian cancer cells

Authors: Fan Zhang, Cui Li, Hailing Liu, Yuexiang Wang, Yile Chen, Xiaoying Wu

Published in: Tumor Biology | Issue 12/2014

Login to get access

Abstract

Vascular endothelial growth factor (VEGF), one of the most important angiogenic factor, can impact the tumor cell proliferation and invasion, but the mechanism remains unclear. This study is to investigate the key proteins which may play an important role in the VEGF-induced progress of ovarian cancer cells. The total protein from HO-8910 cells was separated by two-dimensional electrophoresis (2-DE), and differentially expressed proteins were identified by matrix-assisted laser desorption and ionization time-of-flight tandem mass spectrometry (MALDI-TOF MS) and PDQuest image analysis software. Furthermore, real-time PCR, Western blot, and immunocytochemistry were also used to confirm different expression levels of differential proteins. Morphological changes and invasion capability were evaluated by electron microscope and Matrigel invasion assay, respectively. The highly reproducible and well-resolved 2-DE patterns of both HO-8910/VEGF and HO-8910 cells were acquired. A total of 17 expressed differential proteins were identified, 8 proteins were upregulated (ACTB, TIM, PDIA3, PDIA1, DCTN2, KIC17, SIAS, and KIC10) and 9 downregulated (KIC18, GRP78, CAPG, PPIA, ROA2, LMNA, EZRI, ADRM1, and ENOA). Ultrastructure of VEGF-treated group showed more malignant characteristic compared with control group, an obvious increase in the number of cells penetrating the Matrigel membrane in VEGF-treated group (P < 0.05). These results suggested that VEGF could impact ovarian cancer’s malignant progression by regulating expression of associated proteins.
Literature
1.
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.PubMed
2.
Lockwood-Rayermann S, Donovan HS, Rambo D, Kuo CW. Women’s awareness of ovarian cancer risks and symptoms. Am J Nurs. 2009;109:36–45. quiz 6.PubMed
3.
Igoe BA. Symptoms attributed to ovarian cancer by women with the disease. Nurse Pract. 1997;22:122, 7–8, 30 passim.
4.
Goff BA, Mandel L, Muntz HG, Melancon CH. Ovarian carcinoma diagnosis. Cancer. 2000;89:2068–75.PubMed
5.
de Groote ML, Kazemier HG, Huisman C, van der Gun BT, Faas MM, Rots MG. Upregulation of endogenous ICAM-1 reduces ovarian cancer cell growth in the absence of immune cells. Int J Cancer. 2014;134:280–90.PubMed
6.
Decio A, Taraboletti G, Patton V, Alzani R, Perego P, Fruscio R, et al. Vascular endothelial growth factor c promotes ovarian carcinoma progression through paracrine and autocrine mechanisms. Am J Pathol. 2014;184:1050–61.PubMed
7.
Caye-Thomasen P, Werther K, Nalla A, Bog-Hansen TC, Nielsen HJ, Stangerup SE, et al. VEGF and VEGF receptor-1 concentration in vestibular schwannoma homogenates correlates to tumor growth rate. Otol Neurotol. 2005;26:98–101.PubMed
8.
Yang ZS, Xu YF, Huang FF, Ding GF. Associations of nm23H1, VEGF-C, and VEGF-3 receptor in human prostate cancer. Molecules. 2014;19:6851–62.PubMedPubMedCentral
9.
Garzetti GG, Ciavattini A, Lucarini G, Pugnaloni A, De Nictolis M, Amati S, et al. Vascular endothelial growth factor expression as a prognostic index in serous ovarian cystoadenocarcinomas: relationship with MIB1 immunostaining. Gynecol Oncol. 1999;73:396–401.PubMed
10.
Delli Carpini J, Karam AK, Montgomery L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis. 2010;13:43–58.PubMed
11.
Deng M, Huang H, Jin H, Dirsch O, Dahmen U. The anti-proliferative side effects of AEE788, a tyrosine kinase inhibitor blocking both EGF- and VEGF-receptor, are liver-size-dependent after partial hepatectomy in rats. Invest New Drugs. 2011;29:593–606.PubMed
12.
Zhang D, Li B, Shi J, Zhao L, Zhang X, Wang C, et al. Suppression of tumor growth and metastasis by simultaneously blocking vascular endothelial growth factor (VEGF)-a and VEGF-c with a receptor-immunoglobulin fusion protein. Cancer Res. 2010;70:2495–503.PubMed
13.
Lichtenberger BM, Tan PK, Niederleithner H, Ferrara N, Petzelbauer P, Sibilia M. Autocrine VEGF signaling synergizes with EGFR in tumor cells to promote epithelial cancer development. Cell. 2010;140:268–79.PubMed
14.
Belotti D, Calcagno C, Garofalo A, Caronia D, Riccardi E, Giavazzi R, et al. Vascular endothelial growth factor stimulates organ-specific host matrix metalloproteinase-9 expression and ovarian cancer invasion. Mol Cancer Res. 2008;6:525–34.PubMed
15.
Wang FQ, So J, Reierstad S, Fishman DA. Vascular endothelial growth factor-regulated ovarian cancer invasion and migration involves expression and activation of matrix metalloproteinases. Int J Cancer. 2006;118:879–88.PubMed
16.
Kabbage M, Trimeche M, Ben Nasr H, Hammann P, Kuhn L, Hamrita B, et al. Tropomyosin-4 correlates with higher SBR grades and tubular differentiation in infiltrating ductal breast carcinomas: an immunohistochemical and proteomics-based study. Tumour Biol. 2013;34:3593–602.PubMed
17.
Kabbage M, Trimeche M, Ben Nasr H, Hammann P, Kuhn L, Hamrita B, et al. Expression of the molecular chaperone alphab-crystallin in infiltrating ductal breast carcinomas and the significance thereof: an immunohistochemical and proteomics-based strategy. Tumour Biol. 2012;33:2279–88.PubMed
18.
Toss A, De Matteis E, Rossi E, Casa LD, Iannone A, Federico M, et al. Ovarian cancer: can proteomics give new insights for therapy and diagnosis? Int J Mol Sci. 2013;14:8271–90.PubMedPubMedCentral
19.
Shield-Artin KL, Bailey MJ, Oliva K, Liovic AK, Barker G, Dellios NL, et al. Identification of ovarian cancer-associated proteins in symptomatic women: a novel method for semi-quantitative plasma proteomics. Proteomics Clin Appl. 2012;6:170–81.PubMed
20.
Zhang B, Barekati Z, Kohler C, Radpour R, Asadollahi R, Holzgreve W, et al. Proteomics and biomarkers for ovarian cancer diagnosis. Ann Clin Lab Sci. 2010;40:218–25.PubMed
21.
Faca VM, Hanash SM. In-depth proteomics to define the cell surface and secretome of ovarian cancer cells and processes of protein shedding. Cancer Res. 2009;69:728–30.PubMedPubMedCentral
22.
Chen Y, Ouyang GL, Yi H, Li MY, Zhang PF, Li C, et al. Identification of RKIP as an invasion suppressor protein in nasopharyngeal carcinoma by proteomic analysis. J Proteome Res. 2008;7:5254–62.PubMed
23.
Yang YX, Xiao ZQ, Chen ZC, Zhang GY, Yi H, Zhang PF, et al. Proteome analysis of multidrug resistance in vincristine-resistant human gastric cancer cell line SGC7901/VCR. Proteomics. 2006;6:2009–21.PubMed
24.
Saarelainen SK, Staff S, Peltonen N, Lehtimaki T, Isola J, Kujala PM, et al. Endoglin, VEGF, and its receptors in predicting metastases in endometrial carcinoma. Tumour Biol. 2014;35:4651–7.PubMed
25.
Ji YN, Wang Q, Li Y, Wang Z. Prognostic value of vascular endothelial growth factor a expression in gastric cancer: a meta-analysis. Tumour Biol. 2014;35:2787–93.PubMed
26.
Andisheh-Tadbir A, Khademi B, Kamali F, Fattahi MJ, Malekzadeh M, Taghva M. Upregulation of serum vascular endothelial growth factor and matrix metalloproteinase-3 in patients with oral squamous cell carcinoma. Tumour Biol. 2014;35:5689–93.PubMed
27.
Zhuang Y, Wei M. Impact of vascular endothelial growth factor expression on overall survival in patients with osteosarcoma: a meta-analysis. Tumour Biol. 2014;35:1745–9.PubMed
28.
Yu L, Deng L, Li J, Zhang Y, Hu L. The prognostic value of vascular endothelial growth factor in ovarian cancer: a systematic review and meta-analysis. Gynecol Oncol. 2013;128:391–6.PubMed
29.
Kobel M, Gradhand E, Zeng K, Schmitt WD, Kriese K, Lantzsch T, et al. Ezrin promotes ovarian carcinoma cell invasion and its retained expression predicts poor prognosis in ovarian carcinoma. Int J Gynecol Pathol. 2006;25:121–30.PubMed
30.
Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, et al. Proteomic analysis of lung adenocarcinoma: identification of a highly expressed set of proteins in tumors. Clin Cancer Res. 2002;8:2298–305.PubMed
31.
Tang Y, Nakada MT, Rafferty P, Laraio J, McCabe FL, Millar H, et al. Regulation of vascular endothelial growth factor expression by emmprin via the PI3K-AKT signaling pathway. Mol Cancer Res. 2006;4:371–7.PubMed
32.
Johnson BR, Nitta RT, Frock RL, Mounkes L, Barbie DA, Stewart CL, et al. A-type lamins regulate retinoblastoma protein function by promoting subnuclear localization and preventing proteasomal degradation. Proc Natl Acad Sci U S A. 2004;101:9677–82.PubMedPubMedCentral
33.
Moilanen J, Lassus H, Leminen A, Vaheri A, Butzow R, Carpen O. Ezrin immunoreactivity in relation to survival in serous ovarian carcinoma patients. Gynecol Oncol. 2003;90:273–81.PubMed
34.
Li Q, Gao H, Xu H, Wang X, Pan Y, Hao F, et al. Expression of ezrin correlates with malignant phenotype of lung cancer, and in vitro knockdown of ezrin reverses the aggressive biological behavior of lung cancer cells. Tumour Biol. 2012;33:1493–504.PubMed
35.
Andersson G, Wennersten C, Gaber A, Boman K, Nodin B, Uhlen M, et al. Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts. BMC Urol. 2014;14:36.PubMedPubMedCentral
36.
Jin T, Jin J, Li X, Zhang S, Choi YH, Piao Y, et al. Prognostic implications of ezrin and phosphorylated ezrin expression in non-small cell lung cancer. BMC Cancer. 2014;14:191.PubMedPubMedCentral
37.
Saito S, Yamamoto H, Mukaisho K, Sato S, Higo T, Hattori T, et al. Mechanisms underlying cancer progression caused by ezrin overexpression in tongue squamous cell carcinoma. PLoS One. 2013;8:e54881.PubMedPubMedCentral
38.
Wazir U, Ahmed MH, Bridger JM, Harvey A, Jiang WG, Sharma AK, et al. The clinicopathological significance of lamin A/C, lamin B1 and lamin B receptor mRNA expression in human breast cancer. Cell Mol Biol Lett. 2013;18:595–611.PubMedPubMedCentral
39.
Kong L, Schafer G, Bu H, Zhang Y, Zhang Y, Klocker H. Lamin A/C protein is overexpressed in tissue-invading prostate cancer and promotes prostate cancer cell growth, migration and invasion through the PI3K/AKT/PTEN pathway. Carcinogenesis. 2012;33:751–9.PubMed
40.
Willis ND, Cox TR, Rahman-Casans SF, Smits K, Przyborski SA, van den Brandt P, et al. Lamin A/C is a risk biomarker in colorectal cancer. PLoS One. 2008;3:e2988.PubMedPubMedCentral
41.
Campa MJ, Wang MZ, Howard B, Fitzgerald MC, Patz Jr EF. Protein expression profiling identifies macrophage migration inhibitory factor and cyclophilin a as potential molecular targets in non-small cell lung cancer. Cancer Res. 2003;63:1652–6.PubMed
42.
Wang X, Lu Y, Yang J, Shi Y, Lan M, Liu Z, et al. Identification of triosephosphate isomerase as an anti-drug resistance agent in human gastric cancer cells using functional proteomic analysis. J Cancer Res Clin Oncol. 2008;134:995–1003.PubMed
43.
Yousefi Z, Sarvari J, Nakamura K, Kuramitsu Y, Ghaderi A, Mojtahedi Z. Secretomic analysis of large cell lung cancer cell lines using two-dimensional gel electrophoresis coupled to mass spectrometry. Folia Histochem Cytobiol. 2012;50:368–74.PubMed
44.
Thongwatchara P, Promwikorn W, Srisomsap C, Chokchaichamnankit D, Boonyaphiphat P, Thongsuksai P. Differential protein expression in primary breast cancer and matched axillary node metastasis. Oncol Rep. 2011;26:185–91.PubMed
Metadata
Title
The functional proteomics analysis of VEGF-treated human epithelial ovarian cancer cells
Authors
Fan Zhang
Cui Li
Hailing Liu
Yuexiang Wang
Yile Chen
Xiaoying Wu
Publication date
01-12-2014
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2014
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-014-2552-2

Other articles of this Issue 12/2014

Tumor Biology 12/2014 Go to the issue

Research Article

Single-nucleotide polymorphisms of the PRKCG gene and osteosarcoma susceptibility

Research Article

Annexin A5 promotes invasion and chemoresistance to temozolomide in glioblastoma multiforme cells

Research Article

Zebrafish xenotransplantation model for cancer stem-like cell study and high-throughput screening of inhibitors

Review

The impact of hepatitis B virus x protein and microRNAs in hepatocellular carcinoma: a comprehensive analysis

Research Article

Increased expression of Chitinase 3-like 1 and microvessel density predicts metastasis and poor prognosis in clear cell renal cell carcinoma

Research Article

Targeting the testis-specific heat-shock protein 70-2 (HSP70-2) reduces cellular growth, migration, and invasion in renal cell carcinoma cells
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits